{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:46:26Z","timestamp":1792291586997,"version":"4.4.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40265-024-02131-3","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T12:58:06Z","timestamp":1735390686000},"page":"127-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1444-9266","authenticated-orcid":false,"given":"Violet","family":"Chihota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makaita","family":"Gombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Salazar-Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Ryckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"LaCourse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti S.","family":"Mathad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Mave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"2131_CR1","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024."},{"key":"2131_CR2","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","volume":"2","author":"M Pai","year":"2016","unstructured":"Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2131_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S2213-2600(24)00028-6","volume":"12","author":"AK Coussens","year":"2024","unstructured":"Coussens AK, Zaidi SMA, Allwood BW, Dewan PK, Gray G, Kohli M, et al. Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise. Lancet Respir Med. 2024;12(6):484\u201398.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"2131_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RM Houben","year":"2016","unstructured":"Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10): e1002152.","journal-title":"PLoS Med"},{"issue":"5","key":"2131_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41564-024-01683-0","volume":"9","author":"MA Behr","year":"2024","unstructured":"Behr MA, Edelstein PH, Ramakrishnan L. Rethinking the burden of latent tuberculosis to reprioritize research. Nat Microbiol. 2024;9(5):1157\u20138.","journal-title":"Nat Microbiol"},{"issue":"3","key":"2131_CR6","doi-asserted-by":"publisher","first-page":"1900655","DOI":"10.1183\/13993003.00655-2019","volume":"54","author":"A Cohen","year":"2019","unstructured":"Cohen A, Mathiasen VD, Sch\u00f6n T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.","journal-title":"Eur Respir J"},{"issue":"8","key":"2131_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","volume":"19","author":"GM Knight","year":"2019","unstructured":"Knight GM, McQuaid CF, Dodd PJ, Houben R. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;19(8):903\u201312.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2131_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","volume":"99","author":"GW Comstock","year":"1974","unstructured":"Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131\u20138.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"2131_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001270","volume":"9","author":"AB Suthar","year":"2012","unstructured":"Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7): e1001270.","journal-title":"PLoS Med"},{"issue":"3","key":"2131_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034156","volume":"7","author":"A Gupta","year":"2012","unstructured":"Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS ONE. 2012;7(3): e34156.","journal-title":"PLoS ONE"},{"issue":"8","key":"2131_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/cid\/ciz438","volume":"70","author":"MR Reichler","year":"2020","unstructured":"Reichler MR, Khan A, Sterling TR, Zhao H, Chen B, Yuan Y, et al. Risk factors for tuberculosis and effect of preventive therapy among close contacts of persons with infectious tuberculosis. Clin Infect Dis. 2020;70(8):1562\u201372.","journal-title":"Clin Infect Dis"},{"issue":"10228","key":"2131_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(20)30166-5","volume":"395","author":"L Martinez","year":"2020","unstructured":"Martinez L, Cords O, Horsburgh CR, Andrews JR. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973\u201384.","journal-title":"Lancet"},{"issue":"4","key":"2131_CR13","first-page":"471","volume":"14","author":"S Deuffic-Burban","year":"2010","unstructured":"Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis. 2010;14(4):471\u201381.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"2131_CR14","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1378\/chest.06-2728","volume":"131","author":"R Diel","year":"2007","unstructured":"Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest. 2007;131(5):1424\u201334.","journal-title":"Chest"},{"key":"2131_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100707","volume":"31","author":"Y Jo","year":"2021","unstructured":"Jo Y, Gomes I, Flack J, Salazar-Austin N, Churchyard G, Chaisson RE, et al. Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries. EClinicalMedicine. 2021;31: 100707.","journal-title":"EClinicalMedicine."},{"issue":"1","key":"2131_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/cid\/ciad557","volume":"78","author":"P Kasaie","year":"2024","unstructured":"Kasaie P, Pennington J, Gupta A, Dowdy DW, Kendall EA. The Impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates. Clin Infect Dis. 2024;78(1):133\u201343.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2131_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12916-020-01651-5","volume":"18","author":"S Mandal","year":"2020","unstructured":"Mandal S, Bhatia V, Sharma M, Mandal PP, Arinaminpathy N. The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region: a modelling approach. BMC Med. 2020;18(1):163.","journal-title":"BMC Med"},{"issue":"1","key":"2131_CR18","first-page":"16","volume":"11","author":"O Oxlade","year":"2007","unstructured":"Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2007;11(1):16\u201326.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"2131_CR19","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1016\/S2214-109X(23)00251-6","volume":"11","author":"T Ryckman","year":"2023","unstructured":"Ryckman T, Weiser J, Gombe M, Turner K, Soni P, Tarlton D, et al. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis. Lancet Glob Health. 2023;11(8):e1205\u201316.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"2131_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25629","volume":"23","author":"H Shin","year":"2020","unstructured":"Shin H, Jo Y, Chaisson RE, Turner K, Churchyard G, Dowdy DW. Cost-effectiveness of a 12 country-intervention to scale up short course TB preventive therapy among people living with HIV. J Int AIDS Soc. 2020;23(10): e25629.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"2131_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003712","volume":"18","author":"A Uppal","year":"2021","unstructured":"Uppal A, Rahman S, Campbell JR, Oxlade O, Menzies D. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: a systematic review and meta-analysis. PLoS Med. 2021;18(9): e1003712.","journal-title":"PLoS Med"},{"key":"2131_CR22","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz L, Stagg HR, Abubakar I. Diagnosis and management of latent tuberculosis infection. Cold Spring Harb Perspect Med. 2015;5(11):a017830.","DOI":"10.1101\/cshperspect.a017830"},{"issue":"11","key":"2131_CR23","first-page":"1192","volume":"10","author":"M Farhat","year":"2006","unstructured":"Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192\u2013204.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"2131_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1473-3099(21)00261-9","volume":"22","author":"M Krutikov","year":"2022","unstructured":"Krutikov M, Faust L, Nikolayevskyy V, Hamada Y, Gupta RK, Cirillo D, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-\u03b3 release assays: a systematic review and meta-analysis. Lancet Infect Dis. 2022;22(2):250\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2131_CR25","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.4049\/jimmunol.1103556","volume":"188","author":"CS Lindestam Arlehamn","year":"2012","unstructured":"Lindestam Arlehamn CS, Sidney J, Henderson R, Greenbaum JA, James EA, Moutaftsi M, et al. Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). J Immunol. 2012;188(10):5020\u201331.","journal-title":"J Immunol"},{"issue":"11","key":"2131_CR26","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1093\/cid\/ciad030","volume":"76","author":"E Ortiz-Brizuela","year":"2023","unstructured":"Ortiz-Brizuela E, Apriani L, Mukherjee T, Lachapelle-Chisholm S, Miedy M, Lan Z, et al. Assessing the diagnostic performance of new commercial interferon-\u03b3 release assays for mycobacterium tuberculosis infection: a systematic review and meta-analysis. Clin Infect Dis. 2023;76(11):1989\u201399.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2131_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1378\/chest.11-3157","volume":"142","author":"R Diel","year":"2012","unstructured":"Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-\u03b3 release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest. 2012;142(1):63\u201375.","journal-title":"Chest"},{"key":"2131_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101815","volume":"56","author":"Y Hamada","year":"2023","unstructured":"Hamada Y, Gupta RK, Quartagno M, Izzard A, Acuna-Villaorduna C, Altet N, et al. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. EClinicalMedicine. 2023;56: 101815.","journal-title":"EClinicalMedicine."},{"key":"2131_CR29","volume-title":"Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection (WHO\/UCN\/TB\/2022.1)","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection (WHO\/UCN\/TB\/2022.1). Geneva: World Health Organization; 2022."},{"key":"2131_CR30","volume-title":"WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for TB infection","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for TB infection. Geneva: World Health Organization; 2022."},{"key":"2131_CR31","doi-asserted-by":"publisher","DOI":"10.2471\/B09117","volume-title":"WHO consolidated guidelines on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment. 2nd ed. Geneva: World Health Organization; 2024.","edition":"2"},{"issue":"12","key":"2131_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002573","volume":"3","author":"L Gosc\u00e9","year":"2023","unstructured":"Gosc\u00e9 L, Allel K, Hamada Y, Korobitsyn A, Ismail N, Bashir S, et al. Economic evaluation of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection: a modelling study. PLOS Glob Public Health. 2023;3(12): e0002573.","journal-title":"PLOS Glob Public Health."},{"issue":"6","key":"2131_CR33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5588\/ijtld.17.0758","volume":"22","author":"I Pathmanathan","year":"2018","unstructured":"Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, et al. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis. 2018;22(6):596\u2013605.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2131_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","volume":"56","author":"GJ Fox","year":"2017","unstructured":"Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis. 2017;56:68\u201376.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"2131_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","volume":"17","author":"C Pease","year":"2017","unstructured":"Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2131_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","volume":"167","author":"D Zenner","year":"2017","unstructured":"Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248\u201355.","journal-title":"Ann Intern Med"},{"key":"2131_CR37","volume-title":"WHO operational handbook on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO operational handbook on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment. Geneva: World Health Organization; 2020. (Licence: CC\u00a0BY-NC-SA\u00a03.0 IGO)."},{"issue":"1","key":"2131_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1\u201311.","journal-title":"MMWR Recomm Rep"},{"key":"2131_CR39","doi-asserted-by":"publisher","unstructured":"Salazar-Austin N, Mulder C, Hoddinott G, Ryckman T, Hanrahan CF, Velen K, et al. Preventive treatment for household contacts of drug-susceptible tuberculosis patients. Pathogens. 2022;11(11):1258. https:\/\/doi.org\/10.3390\/pathogens11111258.","DOI":"10.3390\/pathogens11111258"},{"issue":"6","key":"2131_CR40","first-page":"935","volume":"95","author":"GW Comstock","year":"1967","unstructured":"Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95(6):935\u201343.","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"2131_CR41","first-page":"Cd001363","volume":"1999","author":"MJ Smieja","year":"2000","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;1999(2):Cd001363.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2131_CR42","first-page":"827","volume":"119","author":"GW Comstock","year":"1979","unstructured":"Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827\u201330.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"2131_CR43","first-page":"Cd000171","volume":"2010","author":"C Akolo","year":"2010","unstructured":"Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;2010(1):Cd000171.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2131_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"key":"2131_CR45","unstructured":"Clinical Info HIV Gov. Guidelines for the prevention and treatment opportunistic infections in adults and adolescents with HIV. 2024."},{"key":"2131_CR46","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. (Licence: CC\u00a0BY-NC-SA\u00a03.0 IGO)."},{"issue":"9","key":"2131_CR47","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"The TEMPRANO ANRS 12136 Study Group","year":"2015","unstructured":"The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. New Engl J Med. 2015;373(9):808\u201322.","journal-title":"New Engl J Med."},{"issue":"11","key":"2131_CR48","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","volume":"5","author":"A Badje","year":"2017","unstructured":"Badje A, Moh R, Gabillard D, Gu\u00e9hi C, Kabran M, Ntakp\u00e9 JB, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080\u20139.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"2131_CR49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233\u201345.","journal-title":"N Engl J Med"},{"issue":"9944","key":"2131_CR50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","volume":"384","author":"MX Rangaka","year":"2014","unstructured":"Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682\u201390.","journal-title":"Lancet"},{"issue":"1","key":"2131_CR51","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2352-3018(20)30299-X","volume":"8","author":"JM Ross","year":"2021","unstructured":"Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV. 2021;8(1):e8\u201315.","journal-title":"Lancet HIV."},{"issue":"5","key":"2131_CR52","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440\u201353.","journal-title":"N Engl J Med"},{"issue":"5","key":"2131_CR53","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1086\/427802","volume":"40","author":"J Ena","year":"2005","unstructured":"Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40(5):670\u20136.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"2131_CR54","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"4","key":"2131_CR55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/cid\/civ323","volume":"61","author":"TR Sterling","year":"2015","unstructured":"Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis. 2015;61(4):527\u201335.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2131_CR56","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","volume":"30","author":"TR Sterling","year":"2016","unstructured":"Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607\u201315.","journal-title":"AIDS"},{"issue":"3","key":"2131_CR57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","volume":"169","author":"ME Villarino","year":"2015","unstructured":"Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247\u201355.","journal-title":"JAMA Pediatr"},{"issue":"10","key":"2131_CR58","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.7326\/M20-7577","volume":"174","author":"G Churchyard","year":"2021","unstructured":"Churchyard G, C\u00e1rdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al. Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial. Ann Intern Med. 2021;174(10):1367\u201376.","journal-title":"Ann Intern Med"},{"issue":"9","key":"2131_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003738","volume":"18","author":"M Yanes-Lane","year":"2021","unstructured":"Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G, Oxlade O, et al. Tuberculosis preventive therapy for people living with HIV: a systematic review and network meta-analysis. PLoS Med. 2021;18(9): e1003738.","journal-title":"PLoS Med"},{"issue":"2","key":"2131_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/cid\/ciad246","volume":"77","author":"L Melnychuk","year":"2023","unstructured":"Melnychuk L, Perlman-Arrow S, Lisboa Bastos M, Menzies D. A systematic review and meta-analysis of tuberculous preventative therapy adverse events. Clin Infect Dis. 2023;77(2):287\u201394.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2131_CR61","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"},{"key":"2131_CR62","volume-title":"Efficacy, safety, and PK of BIC\/FTC\/TAF in adults with HIV and tuberculosis on rifampicin at week 24","author":"KN Anushka Naidoo","year":"2024","unstructured":"Anushka Naidoo KN, Letsoalo MP, Waalewijn H, Dorse G, Perumal R, Moosa MYS, Osuala EC, Boodhram R, Israelski D, Denti P, Rooney JF, Dooley K. Efficacy, safety, and PK of BIC\/FTC\/TAF in adults with HIV and tuberculosis on rifampicin at week 24. Denver: CROI; 2024."},{"issue":"6","key":"2131_CR63","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","volume":"7","author":"KE Dooley","year":"2020","unstructured":"Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial. Lancet HIV. 2020;7(6):e401\u20139.","journal-title":"Lancet HIV."},{"key":"2131_CR64","volume-title":"Simultaneous initiation in ART-naive PWH of DTG-based ART & 3HP maintains efficacious DTG levels","author":"ED Weld","year":"2024","unstructured":"Weld ED, Solans BP, Salles I, Nonyane BA, Sebe M, Beattie T, Mapendere M, Nielson T, Moodley J, Chihota V, Savic R, Dooley KE, Chaisson RE, Churchyard G. Simultaneous initiation in ART-naive PWH of DTG-based ART & 3HP maintains efficacious DTG levels. Denver: CROI; 2024."},{"key":"2131_CR65","unstructured":"Avihingsanon A, Jirajariyavet S, Ayuthaya TPN, Treebupachatsakul P, Sophonphan J, Visuthranukul J, Danpornpraset D, Imsanguan W, Panarat P, Wilwatrojanagul S, Nooetch P, Natcha N, Gatechompol S, editors. Pharmacokinetics and HIV Viral Load suppression of one month-daily rifapentine and isoniazid (1HP) for tuberculosis preventive therapy among adults with HIV taking standard dolutegrravir based regimens IAS. In: The 25th International AIDS Conference, Munich Germany, 2024."},{"issue":"4","key":"2131_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/cid\/ciz256","volume":"70","author":"KE Dooley","year":"2020","unstructured":"Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020;70(4):549\u201356.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2131_CR67","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3018(23)00081-4","volume":"10","author":"R Griesel","year":"2023","unstructured":"Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, et al. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. Lancet HIV. 2023;10(7):e433\u201341.","journal-title":"Lancet HIV."},{"issue":"6","key":"2131_CR68","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/jac\/dkz068","volume":"74","author":"M Cerrone","year":"2019","unstructured":"Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2131_CR69","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2352-4642(21)00052-3","volume":"5","author":"AA Malik","year":"2021","unstructured":"Malik AA, Farooq S, Jaswal M, Khan H, Nasir K, Fareed U, et al. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2021;5(5):350\u20136.","journal-title":"Lancet Child Adolesc Health."},{"key":"2131_CR70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2334-14-91","volume":"14","author":"J Ayieko","year":"2014","unstructured":"Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis. 2014;14:91.","journal-title":"BMC Infect Dis"},{"key":"2131_CR71","first-page":"28","volume":"26","author":"SH Ferebee","year":"1970","unstructured":"Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28\u2013106.","journal-title":"Bibl Tuberc"},{"key":"2131_CR72","doi-asserted-by":"publisher","unstructured":"Cruz AT, Starke JR. Completion rate and safety of tuberculosis infection treatment with shorter regimens. Pediatrics. 2018;141(2):e20172838. https:\/\/doi.org\/10.1542\/peds.2017-2838.","DOI":"10.1542\/peds.2017-2838"},{"issue":"7","key":"2131_CR73","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/cid\/cix505","volume":"65","author":"AL Sandul","year":"2017","unstructured":"Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085\u201393.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2131_CR74","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1714284","volume":"379","author":"T Diallo","year":"2018","unstructured":"Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379(5):454\u201363.","journal-title":"N Engl J Med"},{"issue":"7","key":"2131_CR75","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/jac\/dkx112","volume":"72","author":"H McIlleron","year":"2017","unstructured":"McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017;72(7):2028\u201334.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2131_CR76","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2352-3018(22)00160-6","volume":"9","author":"A Turkova","year":"2022","unstructured":"Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, et al. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022;9(9):e627\u201337.","journal-title":"Lancet HIV."},{"key":"2131_CR77","volume-title":"WHO consolidated guidelines on tuberculosis Module 5: management of tuberculosis in children and adolescents","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022. (Licence: CC\u00a0BY-NC-SA\u00a03.0 IGO)."},{"issue":"7","key":"2131_CR78","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5588\/ijtld.22.0645","volume":"27","author":"M Strauss","year":"2023","unstructured":"Strauss M, Wademan DT, McInziba A, Hoddinott G, Rafique M, Jola LN, et al. TB preventive therapy preferences among children and adolescents. Int J Tuberc Lung Dis. 2023;27(7):520\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"2131_CR79","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.5588\/ijtld.19.0115","volume":"23","author":"DT Wademan","year":"2019","unstructured":"Wademan DT, Busakwe L, Nicholson TJ, van der Zalm M, Palmer M, Workman J, et al. Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial. Int J Tuberc Lung Dis. 2019;23(12):1263\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"2131_CR80","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1164\/rccm.201106-1083OC","volume":"185","author":"D Zenner","year":"2012","unstructured":"Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185(7):779\u201384.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2131_CR81","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1086\/522182","volume":"45","author":"N Singh","year":"2007","unstructured":"Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis. 2007;45(9):1192\u20139.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2131_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002222","volume":"3","author":"G Simpson","year":"2023","unstructured":"Simpson G, Philip M, Vogel JP, Scoullar MJL, Graham SM, Wilson AN. The clinical presentation and detection of tuberculosis during pregnancy and in the postpartum period in low- and middle-income countries: a systematic review and meta-analysis. PLOS Glob Public Health. 2023;3(8): e0002222.","journal-title":"PLOS Glob Public Health."},{"issue":"6","key":"2131_CR83","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/cix851","volume":"66","author":"N Salazar-Austin","year":"2018","unstructured":"Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: the Tshepiso study. Clin Infect Dis. 2018;66(6):921\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2131_CR84","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/1471-0528.14408","volume":"124","author":"S Sobhy","year":"2017","unstructured":"Sobhy S, Babiker Z, Zamora J, Khan KS, Kunst H. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG. 2017;124(5):727\u201333.","journal-title":"BJOG"},{"key":"2131_CR85","unstructured":"Centers for Disease Control and Prevention. Treatment for TB during pregnancy. In: Division of Tuberculosis Elimination National Center for HIV Viral Hepatitis STD and TB Prevention CDC, editor. 2020."},{"key":"2131_CR86","unstructured":"Clinicalinfo.HIV.Gov. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2024."},{"key":"2131_CR87","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. World Health Organization; 2020.","DOI":"10.30978\/TB2021-2-86"},{"issue":"2","key":"2131_CR88","first-page":"151","volume":"104","author":"AL Franks","year":"1989","unstructured":"Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104(2):151\u20135.","journal-title":"Public Health Rep"},{"issue":"3","key":"2131_CR89","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1164\/ajrccm\/140.3.700","volume":"140","author":"TS Moulding","year":"1989","unstructured":"Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis. 1989;140(3):700\u20135.","journal-title":"Am Rev Respir Dis"},{"issue":"14","key":"2131_CR90","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa1813060","volume":"381","author":"A Gupta","year":"2019","unstructured":"Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333\u201346.","journal-title":"N Engl J Med"},{"issue":"3","key":"2131_CR91","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/cid\/ciad583","volume":"78","author":"A Gupta","year":"2024","unstructured":"Gupta A, Hughes MD, Cruz JL, Avihingsanon A, Mwelase N, Severe P, et al. Adverse pregnancy outcomes among women with human immunodeficiency virus taking isoniazid preventive therapy during the first trimester. Clin Infect Dis. 2024;78(3):667\u201373.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2131_CR92","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1093\/cid\/ciz1224","volume":"71","author":"E Kalk","year":"2020","unstructured":"Kalk E, Heekes A, Mehta U, de Waal R, Jacob N, Cohen K, et al. Safety and effectiveness of isoniazid preventive therapy in pregnant women living with human immunodeficiency virus on antiretroviral therapy: an observational study using linked population data. Clin Infect Dis. 2020;71(8):e351\u20138.","journal-title":"Clin Infect Dis"},{"key":"2131_CR93","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/195637","volume":"2013","author":"AW Taylor","year":"2013","unstructured":"Taylor AW, Mosimaneotsile B, Mathebula U, Mathoma A, Moathlodi R, Theebetsile I, et al. Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol. 2013;2013: 195637.","journal-title":"Infect Dis Obstet Gynecol"},{"key":"2131_CR94","doi-asserted-by":"publisher","unstructured":"Hamada Y, Figueroa C, Mart\u00edn-S\u00e1nchez M, Falzon D, Kanchar A. The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis. Eur Respir J. 2020;55(3):1901967. https:\/\/doi.org\/10.1183\/13993003.01967-2019.","DOI":"10.1183\/13993003.01967-2019"},{"issue":"9","key":"2131_CR95","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/cid\/ciab665","volume":"74","author":"JS Mathad","year":"2021","unstructured":"Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, et al. Pharmacokinetics and safety of 3 months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women. Clinical Infect Dis. 2021;74(9):1604\u201313.","journal-title":"Clinical Infect Dis."},{"key":"2131_CR96","unstructured":"Chihota V, W Z, Cardenas V, Martinson N, Yimer G, Garcia-Basteiro AL, van den Hof S, Chaisson RE, Fielding KL, Churchyard G. OA07-638-19. Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment during pregnancy. In: 52nd world conference on lung health of the international union against tuberculosis and lung disease, 2021; Virtual; 19\u201322 October 2021."},{"key":"2131_CR97","unstructured":"Safety and tolerability of 1 month daily (1HP) and 3 months weekly (3HP) isoniazid and rifapentine with pharmacokinetics of dolutegravir (DTG) in pregnant people with HIV. clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT051220269789240031593."},{"key":"2131_CR98","doi-asserted-by":"crossref","unstructured":"Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH. Red Book: 2021\u20132024 Report of the Committee on Infectious Diseases: American Academy of Pediatrics; 2021.","DOI":"10.1542\/9781610025225"},{"key":"2131_CR99","volume-title":"Tuberculosis preventive treatment: rapid communication","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Tuberculosis preventive treatment: rapid communication. Geneva: World Health Organization; 2024."},{"issue":"5","key":"2131_CR100","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3201\/eid1205.050681","volume":"12","author":"ME Balcells","year":"2006","unstructured":"Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744\u201351.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"2131_CR101","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.5588\/ijtld.15.0908","volume":"20","author":"S den Boon","year":"2016","unstructured":"den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065\u201371.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2131_CR102","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 1\u2014prevention. Tuberculosis preventive treatment, 2nd edn. 2024."},{"key":"2131_CR103","volume-title":"Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO; 2011."},{"issue":"11","key":"2131_CR104","doi-asserted-by":"publisher","first-page":"263","DOI":"10.15585\/mmwr.mm6811a3","volume":"68","author":"A MacNeil","year":"2019","unstructured":"MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global epidemiology of tuberculosis and progress toward achieving global targets\u20142017. MMWR Morb Mortal Wkly Rep. 2019;68(11):263\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2131_CR105","unstructured":"Tsope L, Gombe M, Weiser J, Salazar-Austin N, Mulder C, Ossemane E, et al. Scale-up of short-course TB preventive treatment (3Hp) in high tuberculosis burden countries: the IMpAACT4TB project. In: 53rd Union World Conference on Lung Health; Virtual; 8\u201311 November 2022."},{"key":"2131_CR106","unstructured":"Tsope L, Kennar A, Chimoyi L, Rabothata I, Sisay S, Sithole K, et al. Barriers and facilitators to TB preventive treatment initiation and completion among people living with HIV in three sub-Saharan African countries\u2014SOA08-865-15. In: 54th Union World Conference on Lung Health; Paris, France; 15\u201318 November 2023."},{"issue":"1","key":"2131_CR107","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/ijerph20010621","volume":"20","author":"DG Assefa","year":"2022","unstructured":"Assefa DG, Zeleke ED, Bekele D, Ejigu DA, Molla W, Woldesenbet TT, et al. Isoniazid preventive therapy for prevention of tuberculosis among people living with HIV in Ethiopia: a systematic review of implementation and impacts. Int J Environ Res Public Health. 2022;20(1):621.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2131_CR108","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1186\/s12889-019-7652-x","volume":"19","author":"M Kagujje","year":"2019","unstructured":"Kagujje M, Mubiana ML, Mwamba E, Muyoyeta M. Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. BMC Public Health. 2019;19(1):1329.","journal-title":"BMC Public Health"},{"issue":"5","key":"2131_CR109","doi-asserted-by":"publisher","first-page":"388","DOI":"10.5588\/ijtld.20.0956","volume":"25","author":"N Kalema","year":"2021","unstructured":"Kalema N, Semeere A, Banturaki G, Kyamugabwa A, Ssozi S, Ggita J, et al. Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis. Int J Tuberc Lung Dis. 2021;25(5):388\u201394.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"2131_CR110","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5588\/ijtld.18.0378","volume":"23","author":"J Lai","year":"2019","unstructured":"Lai J, Dememew Z, Jerene D, Abashawl A, Feleke B, Teklu AM, et al. Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2019;23(3):371\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"Suppl 5","key":"2131_CR111","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/01.aids.0000391021.18284.12","volume":"24","author":"R Lester","year":"2010","unstructured":"Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, et al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS. 2010;24(Suppl 5):S45\u20138.","journal-title":"AIDS"},{"issue":"1","key":"2131_CR112","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1186\/s12889-016-3525-8","volume":"16","author":"G Teklay","year":"2016","unstructured":"Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16(1):840.","journal-title":"BMC Public Health"},{"issue":"2","key":"2131_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212035","volume":"14","author":"E Van Ginderdeuren","year":"2019","unstructured":"Van Ginderdeuren E, Bassett J, Hanrahan C, Mutunga L, Van Rie A. Health system barriers to implementation of TB preventive strategies in South African primary care facilities. PLoS ONE. 2019;14(2): e0212035.","journal-title":"PLoS ONE"},{"issue":"12","key":"2131_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024286","volume":"8","author":"EOA Wambiya","year":"2018","unstructured":"Wambiya EOA, Atela M, Eboreime E, Ibisomi L. Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study. BMJ Open. 2018;8(12): e024286.","journal-title":"BMJ Open"},{"issue":"3","key":"2131_CR115","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5588\/pha.17.0011","volume":"7","author":"A Carmone","year":"2017","unstructured":"Carmone A, Rodriguez CA, Frank TD, Kiromat M, Bongi PW, Kuno RG, et al. Increasing isoniazid preventive therapy uptake in an HIV program in rural Papua New Guinea. Public Health Action. 2017;7(3):193\u20138.","journal-title":"Public Health Action."},{"issue":"3","key":"2131_CR116","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5588\/pha.20.0020","volume":"10","author":"G Caturegli","year":"2020","unstructured":"Caturegli G, Materi J, Lombardo A, Milovanovic M, Yende N, Variava E, et al. Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa. Public Health Action. 2020;10(3):118\u201323.","journal-title":"Public Health Action."},{"issue":"10","key":"2131_CR117","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1473-3099(13)70187-7","volume":"13","author":"B Durovni","year":"2013","unstructured":"Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013;13(10):852\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"2131_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25803","volume":"24","author":"S Gengiah","year":"2021","unstructured":"Gengiah S, Barker PM, Yende-Zuma N, Mbatha M, Naidoo S, Taylor M, et al. A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcareclinics in South Africa. J Int AIDS Soc. 2021;24(9): e25803.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"2131_CR119","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1016\/S2352-3018(22)00166-7","volume":"9","author":"E Kakande","year":"2022","unstructured":"Kakande E, Christian C, Balzer LB, Owaraganise A, Nugent JR, DiIeso W, et al. A mid-level health manager intervention to promote uptake of isoniazid preventive therapy among people with HIV in Uganda: a cluster randomised trial. Lancet HIV. 2022;9(9):e607\u201316.","journal-title":"Lancet HIV."},{"issue":"11","key":"2131_CR120","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.5588\/ijtld.13.0315","volume":"17","author":"S Zaeh","year":"2013","unstructured":"Zaeh S, Kempker R, Stenehjem E, Blumberg HM, Temesgen O, Ofotokun I, et al. Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. Int J Tuberc Lung Dis. 2013;17(11):1396\u2013401.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"2131_CR121","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s10461-020-03075-x","volume":"25","author":"T Mabuto","year":"2021","unstructured":"Mabuto T, Mshweshwe-Pakela N, Ntombela N, Hlongwane M, Wong V, Charalambous S, et al. Is HIV post-test counselling aligned with universal test and treat goals? A qualitative analysis of counselling session content and delivery in South Africa. AIDS Behav. 2021;25(5):1583\u201396.","journal-title":"AIDS Behav"},{"key":"2131_CR122","unstructured":"Shearer K, N BA, Mulder C, Nyirenda R, Valverde E, Munguambe S, Kawaza N, Chihota V, Churchyard G, Chaisson R, Golub JE, Hoffmann CJ, C, editor. A choice-architecture based intervention to increase prescribing of TB preventive treatment to people living with HIV in southern Africa: results from a cluster-randomized trial (AS-UnionConf-2023-02347). Union World Conference on Lung Health, Paris, France; 15\u201318 November 2023."},{"issue":"7","key":"2131_CR123","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/09540121.2017.1283390","volume":"29","author":"KB Jacobson","year":"2017","unstructured":"Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi SV. \u201cIt\u2019s about my life\u201d: facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2017;29(7):936\u201342.","journal-title":"AIDS Care"},{"issue":"15","key":"2131_CR124","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.3390\/ijerph17155626","volume":"17","author":"ZS Nezenega","year":"2020","unstructured":"Nezenega ZS, Perimal-Lewis L, Maeder AJ. Factors influencing patient adherence to tuberculosis treatment in Ethiopia: a literature review. Int J Environ Res Public Health. 2020;17(15):5626.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2131_CR125","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s43058-021-00173-2","volume":"2","author":"FC Semitala","year":"2021","unstructured":"Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, et al. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Implement Sci Commun. 2021;2(1):71.","journal-title":"Implement Sci Commun."},{"issue":"Suppl 6","key":"2131_CR126","doi-asserted-by":"publisher","first-page":"s79","DOI":"10.7861\/clinmedicine.16-6-s79","volume":"16","author":"T Wingfield","year":"2016","unstructured":"Wingfield T, Tovar MA, Huff D, Boccia D, Saunders MJ, Datta S, et al. Beyond pills and tests: addressing the social determinants of tuberculosis. Clin Med (Lond). 2016;16(Suppl 6):s79\u201391.","journal-title":"Clin Med (Lond)"},{"key":"2131_CR127","unstructured":"Shapiro AE, van Rooyen H, Schaafsma TT, et al. TB preventive treatment uptake is high in community ART delivery in South Africa. In: Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Seattle; 4\u20139 March 2019."},{"issue":"8","key":"2131_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182185","volume":"12","author":"D Szkwarko","year":"2017","unstructured":"Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: a mixed-methods systematic review. PLoS ONE. 2017;12(8): e0182185.","journal-title":"PLoS ONE"},{"issue":"7","key":"2131_CR129","doi-asserted-by":"publisher","first-page":"612","DOI":"10.5588\/ijtld.21.0558","volume":"26","author":"Y Hirsch-Moverman","year":"2022","unstructured":"Hirsch-Moverman Y, Howard AA, Yuengling KA, Lebelo L, Frederix K, Hesseling AC, et al. Effectiveness of a community-based intervention to prevent childhood TB in Lesotho. Int J Tuberc Lung Dis. 2022;26(7):612\u201322.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"2131_CR130","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049658","volume":"11","author":"H Hussain","year":"2021","unstructured":"Hussain H, Malik A, Ahmed JF, Siddiqui S, Amanullah F, Creswell J, et al. Cost-effectiveness of household contact investigation for detection of tuberculosis in Pakistan. BMJ Open. 2021;11(10): e049658.","journal-title":"BMJ Open"},{"issue":"5","key":"2131_CR131","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/cid\/ciab1047","volume":"75","author":"NA Martinson","year":"2022","unstructured":"Martinson NA, Lebina L, Webb EL, Ratsela A, Varavia E, Kinghorn A, et al. Household contact tracing with intensified tuberculosis and human immunodeficiency virus screening in South Africa: a cluster-randomized trial. Clin Infect Dis. 2022;75(5):849\u201356.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2131_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117009","volume":"10","author":"JN Sekandi","year":"2015","unstructured":"Sekandi JN, Dobbin K, Oloya J, Okwera A, Whalen CC, Corso PS. Cost-effectiveness analysis of community active case finding and household contact investigation for tuberculosis case detection in urban Africa. PLoS ONE. 2015;10(2): e0117009.","journal-title":"PLoS ONE"},{"issue":"5","key":"2131_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248516","volume":"16","author":"Y Hirsch-Moverman","year":"2021","unstructured":"Hirsch-Moverman Y, Howard AA, Mantell JE, Lebelo L, Frederix K, Wills A, et al. Improving child tuberculosis contact identification and screening in Lesotho: results from a mixed-methods cluster-randomized implementation science study. PLoS ONE. 2021;16(5): e0248516.","journal-title":"PLoS ONE"},{"issue":"12","key":"2131_CR134","doi-asserted-by":"publisher","first-page":"e1922","DOI":"10.1016\/S2214-109X(23)00451-5","volume":"11","author":"N Mafirakureva","year":"2023","unstructured":"Mafirakureva N, Tchounga BK, Mukherjee S, Youngui BT, Ssekyanzi B, Simo L, et al. Cost-effectiveness of community-based household tuberculosis contact management for children in Cameroon and Uganda: a modelling analysis of a cluster-randomised trial. Lancet Glob Health. 2023;11(12):e1922\u201330.","journal-title":"Lancet Glob Health"},{"issue":"12","key":"2131_CR135","doi-asserted-by":"publisher","first-page":"e1911","DOI":"10.1016\/S2214-109X(23)00430-8","volume":"11","author":"M Bonnet","year":"2023","unstructured":"Bonnet M, Vasiliu A, Tchounga BK, Cuer B, Fielding K, Ssekyanzi B, et al. Effectiveness of a community-based approach for the investigation and management of children with household tuberculosis contact in Cameroon and Uganda: a cluster-randomised trial. Lancet Glob Health. 2023;11(12):e1911\u201321.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"2131_CR136","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5588\/pha.16.0073","volume":"6","author":"U Egere","year":"2016","unstructured":"Egere U, Sillah A, Togun T, Kandeh S, Cole F, Jallow A, et al. Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia. Public Health Action. 2016;6(4):226\u201331.","journal-title":"Public Health Action."},{"issue":"9","key":"2131_CR137","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/cid\/ciab652","volume":"74","author":"AW Kay","year":"2022","unstructured":"Kay AW, Sandoval M, Mtetwa G, Mkhabela M, Ndlovu B, Devezin T, et al. Vikela Ekhaya: a novel, community-based, tuberculosis contact management program in a high burden setting. Clin Infect Dis. 2022;74(9):1631\u20138.","journal-title":"Clin Infect Dis"},{"key":"2131_CR138","unstructured":"Salazar-Austin N, N B, Cohn S, Mulder C, Mulatu F, Bizuayehu M, Conradie G, Mitiku, P, Golub JE, Chaisson R, Churchyard G, Bedru A, editors. Pragmatic cluster-randomised trial of home-based preventive treatment for TB in Ethiopia (CHIP-TB). OA53-616-17. In: Union Conference on Lung Health; 15\u201318 November 2023; Paris, France."},{"key":"2131_CR139","unstructured":"Malhotra A, B A, Mulatu F, Mulder C, Cohn S, Hanrahan C, Chaisson R, Golub J, Churchyard G, Dowdy D, Sohn H, Salazar-Austin N, editors. Household and health service delivery costs of pediatric home-based versus facility-based TB preventive treatment in Ethiopia (CHIP-TB). OA41-521-17. In: Union Conference on Lung Health; 15\u201318 November 2023; Paris, France."},{"issue":"2","key":"2131_CR140","first-page":"203","volume":"14","author":"SC Cavalcante","year":"2010","unstructured":"Cavalcante SC, Durovni B, Barnes GL, Souza FB, Silva RF, Barroso PF, et al. Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2010;14(2):203\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2131_CR141","first-page":"161","volume":"88","author":"SH Ferebee","year":"1963","unstructured":"Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis. 1963;88:161\u201375.","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"2131_CR142","first-page":"509","volume":"35","author":"O Horwitz","year":"1966","unstructured":"Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ. 1966;35(4):509\u201326.","journal-title":"Bull World Health Organ"},{"key":"2131_CR143","unstructured":"Nyboe J, F A, Christensen OW. Report on tuberculosis chemotherapy pilot project (Tunisia 9). WHO\/TB\/Technical Information\/10. 22 April 1963."},{"issue":"4","key":"2131_CR144","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa1214289","volume":"370","author":"GJ Churchyard","year":"2014","unstructured":"Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;370(4):301\u201310.","journal-title":"N Engl J Med"},{"issue":"8","key":"2131_CR145","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/aje\/kwu320","volume":"181","author":"E Vynnycky","year":"2015","unstructured":"Vynnycky E, Sumner T, Fielding KL, Lewis JJ, Cox AP, Hayes RJ, et al. Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol. 2015;181(8):619\u201332.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2131_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003502","volume":"18","author":"K Dorjee","year":"2021","unstructured":"Dorjee K, Topgyal S, Tsewang T, Tsundue T, Namdon T, Bonomo E, et al. Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment. PLoS Med. 2021;18(1): e1003502.","journal-title":"PLoS Med"},{"issue":"4","key":"2131_CR147","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055295","volume":"12","author":"M Coleman","year":"2022","unstructured":"Coleman M, Hill J, Timeon E, Tonganibeia A, Eromanga B, Islam T, et al. Population-wide active case finding and prevention for tuberculosis and leprosy elimination in Kiribati: the PEARL study protocol. BMJ Open. 2022;12(4): e055295.","journal-title":"BMJ Open"},{"issue":"5","key":"2131_CR148","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/ije\/dyac045","volume":"51","author":"R Ragonnet","year":"2022","unstructured":"Ragonnet R, Williams BM, Largen A, Nasa J, Jack T, Langinlur MK, et al. Estimating the long-term effects of mass screening for latent and active tuberculosis in the Marshall Islands. Int J Epidemiol. 2022;51(5):1433\u201345.","journal-title":"Int J Epidemiol"},{"issue":"9","key":"2131_CR149","doi-asserted-by":"publisher","first-page":"e3476","DOI":"10.1093\/cid\/ciaa857","volume":"73","author":"Y Jo","year":"2021","unstructured":"Jo Y, Shrestha S, Gomes I, Marks S, Hill A, Asay G, et al. Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York, and Texas. Clin Infect Dis. 2021;73(9):e3476\u201382.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2131_CR150","doi-asserted-by":"publisher","first-page":"e1646","DOI":"10.1016\/S2214-109X(22)00372-2","volume":"10","author":"J Zhu","year":"2022","unstructured":"Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, et al. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. Lancet Glob Health. 2022;10(11):e1646\u201354.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"2131_CR151","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1524-4733.2008.00334.x","volume":"11","author":"MC Tan","year":"2008","unstructured":"Tan MC, Marra CA, Sadatsafavi M, Marra F, Mor\u00e1n-Mendoza O, Moadebi S, et al. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health. 2008;11(5):842\u201352.","journal-title":"Value Health."},{"issue":"2","key":"2131_CR152","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1164\/rccm.201501-0069OC","volume":"192","author":"GJ Fox","year":"2015","unstructured":"Fox GJ, Oxlade O, Menzies D. Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness analysis. Am J Respir Crit Care Med. 2015;192(2):229\u201337.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2131_CR153","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004032","volume":"19","author":"NP Nsengiyumva","year":"2022","unstructured":"Nsengiyumva NP, Campbell JR, Oxlade O, Vesga JF, Lienhardt C, Trajman A, et al. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: an analysis of costs and cost-effectiveness. PLoS Med. 2022;19(6): e1004032.","journal-title":"PLoS Med"},{"issue":"8","key":"2131_CR154","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40273-015-0267-x","volume":"33","author":"R Diel","year":"2015","unstructured":"Diel R, Lampenius N, Nienhaus A. Cost effectiveness of preventive treatment for tuberculosis in special high-risk populations. Pharmacoeconomics. 2015;33(8):783\u2013809.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"2131_CR155","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5588\/ijtld.19.0448","volume":"24","author":"L Kawatsu","year":"2020","unstructured":"Kawatsu L, Uchimura K, Ohkado A. A cost-effectiveness study of tuberculosis and latent tuberculosis infection screening in prisons in Japan. Int J Tuberc Lung Dis. 2020;24(5):506\u201311.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2131_CR156","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12890-022-02149-x","volume":"22","author":"J Mahon","year":"2022","unstructured":"Mahon J, Beale S, Holmes H, Arber M, Nikolayevskyy V, Alagna R, et al. A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations. BMC Pulm Med. 2022;22(1):375.","journal-title":"BMC Pulm Med"},{"key":"2131_CR157","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2018.114","volume":"42","author":"EN Silva","year":"2018","unstructured":"Silva EN, Pereira A, de Ara\u00fajo WN, Elias FTS. A systematic review of economic evaluations of interventions to tackle tuberculosis in homeless people. Rev Panam Salud Publica. 2018;42: e40.","journal-title":"Rev Panam Salud Publica"},{"issue":"8","key":"2131_CR158","doi-asserted-by":"publisher","first-page":"741","DOI":"10.5588\/ijtld.21.0676","volume":"26","author":"M Jaswal","year":"2022","unstructured":"Jaswal M, Farooq S, Madhani F, Noorani S, Salahuddin N, Amanullah F, et al. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan. Int J Tuberc Lung Dis. 2022;26(8):741\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"2131_CR159","doi-asserted-by":"publisher","first-page":"823","DOI":"10.5588\/ijtld.21.0293","volume":"25","author":"O Oxlade","year":"2021","unstructured":"Oxlade O, den Boon S, Menzies D, Falzon D, Lane MY, Kanchar A, et al. TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up. Int J Tuberc Lung Dis. 2021;25(10):823\u201331.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2131_CR160","unstructured":"World Health Organization. Consensus meeting report: development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva: World Health Organization; 2017 (WHO\/HTM\/TB\/2017.18). Licence: CC BY-NC-SA3.0 IGO."},{"key":"2131_CR161","volume-title":"Target product profiles for tuberculosis preventive treatment","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Target product profiles for tuberculosis preventive treatment. Geneva: World Health Organization; 2020."},{"issue":"1","key":"2131_CR162","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12916-022-02378-1","volume":"20","author":"JF Vesga","year":"2022","unstructured":"Vesga JF, Lienhardt C, Nsengiyumva P, Campbell JR, Oxlade O, den Boon S, et al. Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis. BMC Med. 2022;20(1):182.","journal-title":"BMC Med"},{"issue":"5","key":"2131_CR163","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1164\/rccm.202012-4541OC","volume":"205","author":"A Kaushik","year":"2022","unstructured":"Kaushik A, Ammerman NC, Tasneen R, Lachau-Durand S, Andries K, Nuermberger E. Efficacy of long-acting bedaquiline regimens in a mouse model of tuberculosis preventive therapy. Am J Respir Crit Care Med. 2022;205(5):570\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2131_CR164","doi-asserted-by":"publisher","first-page":"e00007","DOI":"10.1128\/AAC.00007-19","volume":"63","author":"A Kaushik","year":"2019","unstructured":"Kaushik A, Ammerman NC, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, et al. Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection. Antimicrob Agents Chemother. 2019;63(4):e00007-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2131_CR165","unstructured":"Hobson J, L S-Y, Ammerman N, Massam J, Sharp J, Fotouhi N, Rannard S, Owen A, Nuermberger E, editors. One-dose efficacy of long-acting injectable diarylquinoline in mouse model of TB preventive therapy (Abstract # 881). In: Conference on Retroviruses and Opportunistic Infections (CROI); 3\u20136 March 2024; Denver, Colorado."},{"key":"2131_CR166","unstructured":"Pertinez P, Li SY, Massam J, et al., editors. Long-acting injectable rifapentine with activity in a mouse model of tuberculosis preventive therapy (Poster Session N2, Abstract # 800). In: Conference on Retroviruses and Opportunistic Infections (CROI); 3\u20134 March 2024; Denver, Colorado."},{"issue":"2","key":"2131_CR167","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0924-8579(00)00330-7","volume":"17","author":"M Dutt","year":"2001","unstructured":"Dutt M, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents. 2001;17(2):115\u201322.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2131_CR168","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5588\/ijtld.17.0486","volume":"22","author":"S Swindells","year":"2018","unstructured":"Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, et al. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis. 2018;22(2):125\u201332.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2131_CR169","unstructured":"Branigan D. Injectables redux: developing acceptable long-acting formulations for TB prevention amidst a push for all-oral treatment. Treatment Action Group Report 2024."},{"issue":"12","key":"2131_CR170","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1164\/rccm.202007-2686OC","volume":"203","author":"CAM Mpande","year":"2021","unstructured":"Mpande CAM, Musvosvi M, Rozot V, Mosito B, Reid TD, Schreuder C, et al. Antigen-specific T-cell activation distinguishes between recent and remote tuberculosis infection. Am J Respir Crit Care Med. 2021;203(12):1556\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2131_CR171","doi-asserted-by":"publisher","first-page":"13190","DOI":"10.1038\/s41598-021-92596-z","volume":"11","author":"H Hiza","year":"2021","unstructured":"Hiza H, Hella J, Arbu\u00e9s A, Magani B, Sasamalo M, Gagneux S, et al. Case-control diagnostic accuracy study of a non-sputum CD38-based TAM-TB test from a single milliliter of blood. Sci Rep. 2021;11(1):13190.","journal-title":"Sci Rep"},{"issue":"3","key":"2131_CR172","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1473-3099(20)30914-2","volume":"21","author":"TJ Scriba","year":"2021","unstructured":"Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021;21(3):354\u201365.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2131_CR173","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1093\/cid\/ciab839","volume":"74","author":"JS Sutherland","year":"2022","unstructured":"Sutherland JS, van der Spuy G, Gindeh A, Thuong NTT, Namuganga A, Owolabi O, et al. Diagnostic accuracy of the cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results. Clin Infect Dis. 2022;74(12):2136\u201341.","journal-title":"Clin Infect Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02131-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T11:09:46Z","timestamp":1738840186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02131-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":173,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02131-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"20 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GC and VC were supported by Unitaid through the IMPAACT4TB project (2017-20-IMPAACT4TB). GC is supported by an NIH grant UM1AI068636 for the PHOENIx MDR TB trial. REC was supported by Unitaid through the IMPAACT4TB project (2017-20-IMPAACT4TB) and NIH grant P30AI18436. KED is supported by NIH\/NIAID K24AI150349. MG, AG, NSA, TR, CJH, SL, JSM, and VM have not received funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"VC, MG, AG, NSA, TR, CJM, JSM, VM, and KED have no relevant financial or non-financial interests to disclose. SML is funded by Merck through her institution for C19-related research and declares UpToDate\u2014royalties for a chapter on TB infection in pregnancy. REC\u2019s spouse owns stock in Merck. RC and GC have consulted for Johnson & Johnson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No data are available as this was a review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable. The manuscript is a review and does not report results of a study that involved human participants, their data, or biological material.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. The manuscript does not contain identifiable patient data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable. The article does not contain clinical photos of patients or patient data that could be identifiable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VC and GC conceptualized and designed the outline of the paper. All authors (VC, MG, AG, NSA, TR, CJM, SL, JSM, VM, KED, REC, GC) contributed to specific sections of the manuscript and reviewed the paper. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}